Four-gene signature (SOCS3, MYC, TGIF1, LETM2) accurately diagnoses acute kidney injury after transplantation
Background
Acute kidney injury (AKI) is a frequent and severe complication after renal transplantation, primarily driven by ischemia-reperfusion injury (IRI). AKI significantly increases morbidity and mortality, and can lead to chronic kidney disease. Current diagnostic methods and biomarkers for post-transplant AKI lack sufficient reliability and sensitivity for early detection, leaving a critical gap in timely intervention and improved patient outcomes. Identifying robust, early diagnostic markers is crucial for managing transplant recipients effectively.
Study Design
Researchers analyzed transcriptomic datasets from multiple human cohorts to identify gene signatures associated with transplant-related AKI. A discovery cohort underwent weighted gene co-expression network and differential expression analyses, yielding 222 candidate genes. These were refined in an integrated training cohort using LASSO regression and SVM-RFE to a specific four-gene signature: SOCS3, MYC, TGIF1, and LETM2. The diagnostic performance of this signature was then evaluated in the training cohort and validated in independent external datasets, including a large cohort, and further explored via single-cell transcriptomics.
Results
The identified four-gene signature, comprising SOCS3, MYC, TGIF1, and LETM2, exhibited outstanding discriminative performance for post-transplant AKI. > In the training cohort, the signature achieved an impressive 10-fold cross-validation AUC = 0.969, indicating high accuracy in distinguishing AKI. Validation in independent external datasets, including a large cohort, confirmed this robust performance with an AUC = 0.942. Decision curve analyses highlighted the signature's potential clinical utility for early AKI identification across a broad threshold-probability range, demonstrating favorable performance compared to established biomarkers like neutrophil gelatinase-associated lipocalin. Single-cell transcriptomics revealed cell type-specific expression of these four genes across renal compartments. Furthermore, protein levels of these genes were elevated at 24 h after IRI in mouse kidneys, and showed high expression in human AKI biopsies. Serum protein levels of SOCS3 and LETM2 were also significantly elevated in patients with cardiac surgery-associated AKI, though TGIF1 and MYC did not reach statistical significance in this specific context.
Key Findings
- A four-gene signature (
SOCS3,MYC,TGIF1,LETM2) was identified for post-transplant AKI. - The signature achieved an AUC = 0.969 in the training cohort and AUC = 0.942 in external validation.
- It outperformed established biomarkers like neutrophil gelatinase-associated lipocalin for early AKI identification.
- Protein levels of the four genes were elevated in mouse
IRImodels and human AKI biopsies. - Serum SOCS3 and LETM2 were elevated in cardiac surgery-associated AKI patients.
Why It Matters
This four-gene signature represents a significant step towards earlier and more accurate diagnosis of AKI following kidney transplantation. By providing a highly discriminative biomarker panel, clinicians could potentially identify patients at risk of or experiencing AKI much sooner than with current methods, enabling prompt therapeutic interventions. This could lead to improved patient outcomes, reduced progression to chronic kidney disease, and better long-term allograft survival. While further validation is needed, this research lays the groundwork for a novel diagnostic tool that could integrate into routine post-transplant monitoring protocols, offering a more precise and personalized approach to managing transplant recipients.